Vudalimab
Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation[1].
Product Specifications
CAS Number
2329669-72-7
UNSPSC
12352203
Target
CTLA-4; PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/vudalimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Vudalimab]
Molecular Weight
(144.5 kDa)
References & Citations
[1]Hedvat M, et, al. Dual Blockade of PD1 and CTLA4 with Bispecific Antibody XmAb20717 Promotes Human T Cell Activation and Proliferation.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
